PUBLISHER: TechNavio | PRODUCT CODE: 2144895
PUBLISHER: TechNavio | PRODUCT CODE: 2144895
Global Blood Plasma Market 2026-2030
The global blood plasma market is forecasted to grow by USD 20348.5 mn during 2025-2030, accelerating at a CAGR of 9.2% during the forecast period. The report on the global blood plasma market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising immunodeficiency and autoimmune disease burden, rising bleeding disorder burden and clotting factor demand, infrastructure expansion and strategic plasma investments.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
| Market Scope | |
|---|---|
| Base Year | 2025 |
| End Year | 2030 |
| Series Year | 2026-2030 |
| Growth Momentum | Accelerate |
| YOY 2026 | 8.7% |
| CAGR | 9.2% |
| Incremental Value | $20348.5 mn |
Technavio's global blood plasma market is segmented as below:
By Application
- Therapeutic use
- Diagnostic use
- Research and development
By Source
- Human plasma
- Synthetic plasma
By Product Type
- Immunoglobulins
- Albumin
- Coagulation factors
- Hyperimmune globulins
- Others
Geography
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Asia
- Rest of World (ROW)
- Rest of World (ROW)
This study identifies the next generation chromatography and yield technologies as one of the prime reasons driving the global blood plasma market growth during the next few years. Also, scaling and automation across plasma collection centers and rising clinical demand for neurological and hematological therapies will lead to sizable demand in the market.
The report on the global blood plasma market covers the following areas:
- Global blood plasma market sizing
- Global blood plasma market forecast
- Global blood plasma market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global blood plasma market vendors that include ADMA Biologics Inc., Bharat Serums and Vaccines Ltd., BioIVT LLC, Biotest AG, CSL Behring, Evolve Biologics Inc., GC Biopharma Corp., Grifols SA, Kamada Ltd., Kedrion SpA, KM Biologics Co. Ltd., LFB SA, Meiji Holdings Co. Ltd., Octapharma AG, PlasmaGen BioSciences Pvt. Ltd., Prothya Biosolutions, SK Plasma Co. Ltd., Takeda Pharmaceutical Ltd., Terumo Corp.. Also, the global blood plasma market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
- 1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market by Geography
- Executive Summary - Chart on Market Segmentation by Application
- Executive Summary - Chart on Market Segmentation by Source
- Executive Summary - Chart on Market Segmentation by Product Type
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis
- 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- 2.2 Criticality of inputs and Factors of differentiation
- 2.3 Factors of disruption
- 2.4 Impact of drivers and challenges
3 Market Landscape
- 3.1 Market ecosystem
- 3.2 Market characteristics
- 3.3 Value chain analysis
4 Market Sizing
- 4.1 Market definition
- 4.2 Market segment analysis
- Market segments
- 4.3 Market size 2025
- 4.4 Market outlook: Forecast for 2025-2030
5 Historic Market Size
- 5.1 Global Blood Plasma Market 2020 - 2024
- Historic Market Size - Data Table on Global Blood Plasma Market 2020 - 2024 ($ million)
- 5.2 Application segment analysis 2020 - 2024
- Historic Market Size - Application Segment 2020 - 2024 ($ million)
- 5.3 Source segment analysis 2020 - 2024
- Historic Market Size - Source Segment 2020 - 2024 ($ million)
- 5.4 Product Type segment analysis 2020 - 2024
- Historic Market Size - Product Type Segment 2020 - 2024 ($ million)
- 5.5 Geography segment analysis 2020 - 2024
- Historic Market Size - Geography Segment 2020 - 2024 ($ million)
- 5.6 Country segment analysis 2020 - 2024
- Historic Market Size - Country Segment 2020 - 2024 ($ million)
6 Qualitative Analysis
- 6.1 Impact of AI on Global Blood Plasma Market
- 6.2 Impact of Geopolitical Conflict on Global Blood Plasma Market
7 Five Forces Analysis
- 7.1 Five forces summary
- Five forces analysis - Comparison between 2025 and 2030
- 7.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2025 and 2030
- 7.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2025 and 2030
- 7.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2025 and 2030
- 7.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2025 and 2030
- 7.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2025 and 2030
- 7.7 Market condition
8 Market Segmentation by Application
- 8.1 Market segments
- 8.2 Comparison by Application
- 8.3 Therapeutic use - Market size and forecast 2025-2030
- 8.4 Diagnostic use - Market size and forecast 2025-2030
- 8.5 Research and development - Market size and forecast 2025-2030
- 8.6 Market opportunity by Application
- Market opportunity by Application ($ million)
9 Market Segmentation by Source
- 9.1 Market segments
- 9.2 Comparison by Source
- 9.3 Human plasma - Market size and forecast 2025-2030
- 9.4 Synthetic plasma - Market size and forecast 2025-2030
- 9.5 Market opportunity by Source
- Market opportunity by Source ($ million)
10 Market Segmentation by Product Type
- 10.1 Market segments
- 10.2 Comparison by Product Type
- 10.3 Immunoglobulins - Market size and forecast 2025-2030
- 10.4 Albumin - Market size and forecast 2025-2030
- 10.5 Coagulation factors - Market size and forecast 2025-2030
- 10.6 Hyperimmune globulins - Market size and forecast 2025-2030
- 10.7 Others - Market size and forecast 2025-2030
- 10.8 Market opportunity by Product Type
- Market opportunity by Product Type ($ million)
11 Customer Landscape
- 11.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
12 Geographic Landscape
- 12.1 Geographic segmentation
- 12.2 Geographic comparison
- 12.3 North America - Market size and forecast 2025-2030
- 12.3.1 US - Market size and forecast 2025-2030
- 12.3.2 Canada - Market size and forecast 2025-2030
- 12.3.3 Mexico - Market size and forecast 2025-2030
- 12.4 Europe - Market size and forecast 2025-2030
- 12.4.1 Germany - Market size and forecast 2025-2030
- 12.4.2 UK - Market size and forecast 2025-2030
- 12.4.3 France - Market size and forecast 2025-2030
- 12.4.4 Italy - Market size and forecast 2025-2030
- 12.4.5 Spain - Market size and forecast 2025-2030
- 12.4.6 The Netherlands - Market size and forecast 2025-2030
- 12.5 Asia - Market size and forecast 2025-2030
- 12.5.1 China - Market size and forecast 2025-2030
- 12.5.2 India - Market size and forecast 2025-2030
- 12.5.3 Japan - Market size and forecast 2025-2030
- 12.5.4 South Korea - Market size and forecast 2025-2030
- 12.5.5 Indonesia - Market size and forecast 2025-2030
- 12.5.6 Thailand - Market size and forecast 2025-2030
- 12.6 Rest of World (ROW) - Market size and forecast 2025-2030
- 12.6.1 Brazil - Market size and forecast 2025-2030
- 12.6.2 Saudi Arabia - Market size and forecast 2025-2030
- 12.6.3 UAE - Market size and forecast 2025-2030
- 12.6.4 Turkey - Market size and forecast 2025-2030
- 12.6.5 Argentina - Market size and forecast 2025-2030
- 12.6.6 Colombia - Market size and forecast 2025-2030
- 12.6.7 South Africa - Market size and forecast 2025-2030
- 12.6.8 Israel - Market size and forecast 2025-2030
- 12.7 Market opportunity by geography
- Market opportunity by geography ($ million)
- Data Tables on Market opportunity by geography ($ million)
13 Drivers, Challenges, and Opportunity
- 13.1 Market drivers
- Rising immunodeficiency and autoimmune disease burden
- Rising bleeding disorder burden and clotting factor demand
- Infrastructure expansion and strategic plasma investments
- 13.2 Market challenges
- Stringent regulatory and ethical compliance standards
- Vulnerability of supply chain and collection infrastructure
- High cost of plasma therapies and reimbursement complexities
- 13.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2025 and 2030
- 13.4 Market opportunities
- Next generation chromatography and yield technologies
- Scaling and automation across plasma collection centers
- Rising clinical demand for neurological and hematological therapies
14 Competitive Landscape
- 14.1 Overview
- 14.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
- 14.3 Landscape disruption
- Overview on factors of disruption
- 14.4 Industry risks
- Impact of key risks on business
15 Competitive Analysis
- 15.1 Companies profiled
- Companies covered
- 15.2 Company ranking index
- Company ranking index
- 15.3 Market positioning of companies
- Matrix on companies position and classification
- 15.4 Bharat Serums and Vaccines Ltd.
- Bharat Serums and Vaccines Ltd. - Overview
- Bharat Serums and Vaccines Ltd. - Product / Service
- Bharat Serums and Vaccines Ltd. - Key offerings
- SWOT
- 15.5 BioIVT LLC
- BioIVT LLC - Overview
- BioIVT LLC - Product / Service
- BioIVT LLC - Key offerings
- SWOT
- 15.6 Biotest AG
- Biotest AG - Overview
- Biotest AG - Business segments
- Biotest AG - Key offerings
- Biotest AG - Segment focus
- SWOT
- 15.7 CSL Behring
- CSL Behring - Overview
- CSL Behring - Product / Service
- CSL Behring - Key offerings
- SWOT
- 15.8 GC Biopharma Corp.
- GC Biopharma Corp. - Overview
- GC Biopharma Corp. - Business segments
- GC Biopharma Corp. - Key offerings
- GC Biopharma Corp. - Segment focus
- SWOT
- 15.9 Grifols SA
- Grifols SA - Overview
- Grifols SA - Business segments
- Grifols SA - Key offerings
- Grifols SA - Segment focus
- SWOT
- 15.10 Kamada Ltd.
- Kamada Ltd. - Overview
- Kamada Ltd. - Business segments
- Kamada Ltd. - Key offerings
- Kamada Ltd. - Segment focus
- SWOT
- 15.11 Kedrion SpA
- Kedrion SpA - Overview
- Kedrion SpA - Product / Service
- Kedrion SpA - Key offerings
- SWOT
- 15.12 KM Biologics Co. Ltd.
- KM Biologics Co. Ltd. - Overview
- KM Biologics Co. Ltd. - Product / Service
- KM Biologics Co. Ltd. - Key offerings
- SWOT
- 15.13 LFB SA
- LFB SA - Overview
- LFB SA - Product / Service
- LFB SA - Key offerings
- SWOT
- 15.14 Meiji Holdings Co. Ltd.
- Meiji Holdings Co. Ltd. - Overview
- Meiji Holdings Co. Ltd. - Business segments
- Meiji Holdings Co. Ltd. - Key offerings
- Meiji Holdings Co. Ltd. - Segment focus
- SWOT
- 15.15 Octapharma AG
- Octapharma AG - Overview
- Octapharma AG - Product / Service
- Octapharma AG - Key offerings
- SWOT
- 15.16 Prothya Biosolutions
- Prothya Biosolutions - Overview
- Prothya Biosolutions - Product / Service
- Prothya Biosolutions - Key offerings
- SWOT
- 15.17 Takeda Pharmaceutical Ltd.
- Takeda Pharmaceutical Ltd. - Overview
- Takeda Pharmaceutical Ltd. - Business segments
- Takeda Pharmaceutical Ltd. - Key news
- Takeda Pharmaceutical Ltd. - Key offerings
- Takeda Pharmaceutical Ltd. - Segment focus
- SWOT
- 15.18 Terumo Corp.
- Terumo Corp. - Overview
- Terumo Corp. - Business segments
- Terumo Corp. - Key news
- Terumo Corp. - Key offerings
- Terumo Corp. - Segment focus
- SWOT
16 Appendix
- 16.1 Scope of the report
- Market definition
- Objectives
- Notes and caveats
- 16.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
- 16.3 Currency conversion rates for US$
- Currency conversion rates for US$
- 16.4 Research methodology
- Research methodology
- 16.5 Data procurement
- Information sources
- 16.6 Data validation
- Data validation
- 16.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
- 16.8 Data synthesis
- Data synthesis
- 16.9 360 degree market analysis
- 360 degree market analysis
- 16.10 List of abbreviations
- List of abbreviations
